Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 8/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | AKT1 | P31749 | 2/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.36 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5630964 | 1.00 | LMNA (0.42) | LMNAKMT2AEGFRPIK3CDPIK3CB | |
| SCHEMBL14462362 | 0.89 | LMNA (0.42) | LMNAKMT2AEGFRPIK3CDPIK3CB | |
| SCHEMBL4986029 | 0.85 | LMNA (0.48) | LMNAKMT2AEGFRPIK3CDPIK3CB | |
| SCHEMBL4985998 | 0.85 | LMNA (0.48) | LMNAKMT2AEGFRPIK3CDPIK3CB | |
| SCHEMBL5630983 | 0.84 | IDO1 (0.52) | — | |
| SCHEMBL5631270 | 0.83 | EGFR (0.47) | LMNAKMT2AEGFRERBB2ERBB4 | |
| SCHEMBL5631259 | 0.83 | EGFR (0.47) | LMNAKMT2AEGFRERBB2ERBB4 | |
| SCHEMBL5630752 | 0.83 | LMNA (0.42) | LMNAKMT2AEGFRPIK3CDPIK3CB | |
| SCHEMBL5630763 | 0.83 | LMNA (0.42) | LMNAKMT2AEGFRPIK3CDPIK3CB | |
| SCHEMBL5631477 | 0.83 | LMNA (0.47) | LMNAKMT2AEGFRPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971583-B1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORP (US) | 2015-03-25 | — | — | EP | claimed |
| US-8951536-B2 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2015-02-10 | — | — | US | claimed |
| US-8450351-B2 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2013-05-28 | — | — | US | claimed |
| US-20070185165-A1 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION | 2007-08-09 | — | — | US | claimed |
| EP-1971583-B1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORP (US) | 2015-03-25 | — | — | EP | disclosed |
| US-8951536-B2 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2015-02-10 | — | — | US | disclosed |
| US-20130177590-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2013-07-11 | — | — | US | disclosed |
| US-8450351-B2 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450351-B2 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2013-05-28 | — | — | US | disclosed |
| US-20070185165-A1 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION | 2007-08-09 | — | — | US | disclosed |
| US-20070185165-A1 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130177590-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, HNMT | LMNA 4520/4885KMT2A 545/4885EGFR 1553/4885 |
| US-20070185165-A1 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | IDO1, IDO2, HNMT | LMNA 4520/4885KMT2A 545/4885EGFR 1553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.